Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Canadeo A, Giever E, Szabo A, Jin Y, Winer E, Badar T, Campos J, Lin C, Anderson C, Shallis R, Muradashvili T, Coltoff A, Guo Q, Patel A, Goldberg L, Abaza Y, Fariduddin M, Ayoub R, Foucar C, Nai N, Kota V, Dalgetty M, Gold M, Guduru M, Atallah E. Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium. Blood 2024, 144: 5174-5174. DOI: 10.1182/blood-2024-198914.Peer-Reviewed Original ResearchWhite blood cell countAcute promyelocytic leukemiaIncidence of relapseHigh-risk diseaseAll-trans retinoic acidOverall survivalDifferentiation syndromeHigh riskArsenic trioxideInduction regimenTreatment regimensSupportive care strategiesCardiovascular comorbiditiesMedian white blood cell countData collection formDoses of gemtuzumab ozogamicinIncidence of CNS relapseIncidence of differentiation syndromeLow incidence of relapseOutcome of APL patientsSuspected acute promyelocytic leukemiaCumulative incidence of relapseDiagnosis of acute promyelocytic leukemiaLow-risk acute promyelocytic leukemiaMortality rate